ATE375400T1 - Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren - Google Patents

Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren

Info

Publication number
ATE375400T1
ATE375400T1 AT03761599T AT03761599T ATE375400T1 AT E375400 T1 ATE375400 T1 AT E375400T1 AT 03761599 T AT03761599 T AT 03761599T AT 03761599 T AT03761599 T AT 03761599T AT E375400 T1 ATE375400 T1 AT E375400T1
Authority
AT
Austria
Prior art keywords
hiv
correlate
drug
drugs
reverse transcriptase
Prior art date
Application number
AT03761599T
Other languages
English (en)
Inventor
Hilde Azijn
Bethune Marie-Pierre T M M De
Johan Vingerhoets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE375400T1 publication Critical patent/ATE375400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03761599T 2002-07-01 2003-06-30 Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren ATE375400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39302502P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
ATE375400T1 true ATE375400T1 (de) 2007-10-15

Family

ID=30000963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761599T ATE375400T1 (de) 2002-07-01 2003-06-30 Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren

Country Status (6)

Country Link
EP (1) EP1520036B1 (de)
AT (1) ATE375400T1 (de)
AU (1) AU2003251731C1 (de)
CA (1) CA2490918A1 (de)
DE (1) DE60316807T2 (de)
WO (1) WO2004003227A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9704637A (pt) * 1996-01-26 1998-06-09 Innogenetics Nv Processo para deteção de mutações induzidas por droga no gene de transcrição reversa
MXPA01012270A (es) * 1999-05-28 2003-06-24 Virco Nv Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos.
EP1194587A4 (de) * 1999-06-22 2005-07-06 Virologic Inc Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids
ATE422049T1 (de) * 2000-10-20 2009-02-15 Virco Bvba Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz

Also Published As

Publication number Publication date
AU2003251731C1 (en) 2009-03-05
DE60316807T2 (de) 2008-07-17
EP1520036B1 (de) 2007-10-10
AU2003251731B2 (en) 2008-09-18
WO2004003227A1 (en) 2004-01-08
EP1520036A1 (de) 2005-04-06
CA2490918A1 (en) 2004-01-08
DE60316807D1 (de) 2007-11-22
AU2003251731A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Scott et al. Australia needs to increase testing to achieve hepatitis C elimination
Hellard et al. Hepatitis C transmission and treatment as prevention–The role of the injecting network
Karim et al. HIV/Aids in South Africa
Hillhouse et al. Predicting in‐treatment performance and post‐treatment outcomes in methamphetamine users
ATE217105T1 (de) Verfahren und vorrichtung zur unterstützung eines benutzers zum erzeugen eines medizinischen protokolls
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
Newman et al. Willingness to participate in HIV vaccine trials: the impact of trial attributes
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
DE60316807D1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Jaiswal et al. Study on patient’s awareness towards role of artificial intelligence in dentistry
Kostaki et al. Validation of molecular clock inferred HIV infection ages: Evidence for accurate estimation of infection dates
EP1407042A4 (de) Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids
Hoff et al. Looking for men in all the wrong places…: HIV prevention small-group programs do not reach high risk gay men
Martinello et al. Cure and Control: What Will It Take to Eliminate HCV?
KR200208239Y1 (ko) 특정인의 ｄｎａ구조를 형상화한 팔찌
Markby et al. DEMONSTRATION OF THE FEASIBILITY OF TWO INNOVATIVE MODELS OF HCV TESTING & TREATMENT IN TWO UNIQUE POPULATIONS IN PUNJAB & DELHI, INDIA–THE HEAD-START PROJECT–INDIA
BR0111575A (pt) Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
DIVERSE Session 1020 (Symposium)
Minteer et al. A DNAmCULTURE Epigenetic Fingerprint Recapitulates Physiological Aging
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Schiavi et al. Early Occupational Therapy Intervention: Patients’ Occupational Needs
Gani Stochastic modelling of AIDS epidemiology and HIV pathogenesis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1520036

Country of ref document: EP